2026-02-24
Vision and Age-Related Macular Degeneration: Lutein, Zeaxanthin, and AREDS2 Evidence
The AREDS2 trial established lutein and zeaxanthin as replacements for beta-carotene in the AMD supplement formula, reducing progression risk by 25% in high-risk eyes. Dietary intake from dark leafy greens provides equivalent carotenoids. This article explains what the evidence supports and what it does not.
2026-02-18
Partial Epigenetic Reprogramming for Vision Loss: Life Biosciences ER-100 Trial
Life Biosciences received FDA clearance to begin the first human trial of partial epigenetic reprogramming using OSK Yamanaka factors delivered via AAV for glaucoma and NAION. Trial is in early stages; no human efficacy data exists yet.
2026-02-10
NMN and Brain Aging: Preclinical Signal and Human Trial Uncertainty
NMN is a NAD+ precursor with strong mechanistic rationale and preclinical signal, but current human cognition data remain mixed and incomplete.
2026-02-03
Eye Health and Macular Degeneration Prevention: AREDS2 Formula, Lutein, and Zeaxanthin
Age-related macular degeneration (AMD) is the leading cause of vision loss in older adults. The AREDS2 trial established that high-dose lutein, zeaxanthin, vitamins C and E, and zinc slow progression in intermediate-to-advanced AMD. Prevention evidence for early-stage disease is less definitive.